LEGN

Legend Biotech Corp ADR

22.66

Nov 05 • 2:41 PM ET -0.11 (-0.51%)

Healthcare Biotechnology USA Mid NASD

Nov 04, 9:06 AMLegend Biotech to present CARVYKTI and pipeline data at ASH 2026, including early 100% responses for in vivo CAR-T LB2501

Peers: AUTL BMY ALLO GILD IOVA JNJ CRBU IMTX KYTX CABA

| Held by: IBB IEMG PBE CANC EEM MCHI GNOM IXUS FBCG SPEM

Scroll to Statements

Index	-
Market Cap	4.39B
Enterprise Value	3.70B
Income	-91.90M
Sales	1.27B
Book/sh	6.35
Cash/sh	4.98
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	2900
IPO	Jun 05, 2020

P/E	-
Forward P/E	41.85
PEG	-
P/S	3.44
P/B	3.57
P/C	4.55
P/FCF	-
EV/EBITDA	-
EV/Sales	2.91
Quick Ratio	2.94
Current Ratio	3.04
Debt/Eq	0.23
LT Debt/Eq	0.09
Option/Short	Yes / Yes

EPS (ttm)	-0.51
EPS next Y	0.54
EPS next Q	-0.00
EPS this Y	94.69%
EPS next Y	1357.95%
EPS next 5Y	-
EPS past 3/5Y	16.80% 6.49%
Sales past 3/5Y	106.67% 68.87%
EPS Y/Y TTM	71.96%
Sales Y/Y TTM	59.59%
EPS Q/Q	125.11%
Sales Q/Q	51.64%
Earnings	Nov 10 BMO
EPS/Sales Surpr.	59.86% 8.86%

Insider Own	4.60%
Insider Trans	-0.43%
Inst Own	50.59%
Inst Trans	1.69%
ROA	-5.34%
ROE	-8.11%
ROIC	-6.86%
Gross Margin	53.00%
Oper. Margin	-4.12%
Profit Margin	-7.21%
SMA20	12.57%
SMA50	15.48%
SMA200	2.37%
Trades

Shs Outstand	193.77M
Shs Float	184.85M
Short Float	7.52%
Short Ratio	6.55
Short Interest	13.90M
52W High	37.50 -39.59%
52W Low	16.24 39.50%
Volatility	4.98% 5.57%
ATR (14)	1.15
RSI (14)	64.73
Beta	0.55
Rel Volume	1.23
Avg Volume	2.12M
Volume	2,109,088

Perf Week	1.59%
Perf Month	18.49%
Perf Quarter	9.18%
Perf Half Y	-20.70%
Perf YTD	4.21%
Perf Year	-29.23%
Perf 3Y	-65.66%
Perf 5Y	-53.49%
Perf 10Y	-
Recom	1.71
Target Price	45.21
Prev Close	22.77
Price	22.66
Change %	-0.51%

Consensus

Buy

Avg. Price Target

$45.21

Implied Upside

+99.6%

Analysts16incl. previous ratings

Rating Distribution10 Buy · 6 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 12, 2026	Downgrade	OOppenheimer	Outperform → Perform
Jul 24, 2026	Downgrade	UUBS	Buy → Neutral	$28	+23.6%
Jul 13, 2026	Resumed	JJP Morgan	Neutral	$35	+54.5%
Feb 12, 2026	Downgrade	RRothschild & Co Redburn	Buy → Neutral	$24	+5.9%
Jan 22, 2026	Downgrade	TTD Cowen	Buy → Hold	$21	-7.3%
Jan 07, 2026	Initiated	OOppenheimer	Outperform	$75	+231.1%
Oct 07, 2025	Initiated	CCantor Fitzgerald	Overweight	$40	+76.6%
Oct 08, 2024	Initiated	RRedburn Atlantic	Buy	$86	+279.6%
Jun 17, 2024	Initiated	TTruist	Buy	$88	+288.4%
May 24, 2024	Reiterated	HH.C. Wainwright	Buy	$86 → $73	+222.2%
May 23, 2024	Initiated	DDeutsche Bank	Buy	$60	+164.8%
Apr 17, 2024	Upgrade	BScotiabank	Sector Perform → Sector Outperform	$65	+186.9%
Apr 03, 2024	Initiated	CCantor Fitzgerald	Overweight	$82	+262.0%
Mar 13, 2024	Initiated	RRaymond James	Outperform	$86	+279.6%
Dec 19, 2023	Initiated	BScotiabank	Sector Perform
Nov 06, 2023	Initiated	GGoldman	Buy	$90.09	+297.7%
May 25, 2023	Initiated	WWilliam Blair	Mkt Perform	$64	+182.5%
May 22, 2023	Initiated	DDaiwa Securities	Buy
Mar 29, 2023	Initiated	HH.C. Wainwright	Buy	$66	+191.3%
Mar 24, 2023	Initiated	RRBC Capital Mkts	Outperform	$73	+222.2%

Nov-04-26 09:00AM	Legend Biotech to Showcase CARVYKTI Leadership and Next-Generation Cell Therapy Innovation at ASH 2026 (GlobeNewswire) +6.01%
Nov-03-26 06:15AM	How to Invest in the Rise of China's Biotech: Buy U.S. Drug Stocks (Barrons.com)
12:19AM	Legend Biotech Must Prove Its First Profit Was No Fluke As Margins Reset (Earnings Whispers)
Oct-27-26 08:00AM	Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results (GlobeNewswire) +5.74%
Oct-15-26 08:00AM	Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy (GlobeNewswire)
09:00AM	Loading…
Oct-01-26 09:00AM	Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma (GlobeNewswire)
Sep-25-26 07:00AM	Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion (GlobeNewswire)
Sep-15-26 07:40PM	LEGNs New CEO From Novartis Paves Way For Buyout Speculation (Stocktwits)
08:00AM	Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer (GlobeNewswire)
07:30AM	Legend Naming Novartis Executive as CEO (The Wall Street Journal)
Sep-10-26 08:00AM	Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting (GlobeNewswire)
Sep-01-26 08:00AM	Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
05:08AM	The hidden scale-out problem behind CAR-Ts growth (Pharma Voice)
Aug-11-26 03:00PM	Legend Biotech Corp (LEGN) (Q2 2026) Earnings Call Highlights: First Profitable Quarter Driven ... (GuruFocus.com) +5.66%
10:25AM	Legend Biotech shares rise 5% as Q2 earnings and revenue beat estimates (InvestorsHub)
08:12AM	Loading…
08:12AM	Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs (BioPharma Dive)
07:00AM	Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights (GlobeNewswire)
Jul-28-26 11:35AM	Leadership changes afoot at two CGT biotechs (Pharmaceutical Technology)
08:00AM	Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results (GlobeNewswire)
Jul-27-26 02:35PM	LEGN Stock Plunges 15% After Sudden CEO Exit But Analyst Reiterates Optimism In Companys Under-Development Lymphoma Asset (Stocktwits) -13.28%
01:01PM	?? Under the Radar: Legend Stock Tumbles After CEO's Abrupt Departure (The Wall Street Journal)
07:00AM	FDA scientists question Capricor data; Legend CEO steps down (BioPharma Dive)
06:00AM	Legend Biotech Announces CEO Transition (GlobeNewswire)
Jun-17-26 09:21PM	Legend Biotech Corporation Announces Pricing of Public Offering (GlobeNewswire) -16.68%
04:29PM	Legend Biotech Corporation Announces Proposed Public Offering (GlobeNewswire)
Jun-15-26 08:00AM	Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (GlobeNewswire)
Jun-14-26 03:15AM	Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (GlobeNewswire)
Jun-11-26 03:56PM	Imviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates (Exec Edge)
Jun-03-26 07:57AM	Legend surges on early data for in vivo lymphoma cell therapy (BioPharma Dive)
Jun-02-26 11:28AM	ASCO 2026: Mixed SCLC result for Legends LB2102, Novartis expedites manufacture (Pharmaceutical Technology) +42.22%
09:38AM	Loading…
09:38AM	Legend's Cancer-Fighter Notches Elusive 100% Success Rate; What's Next? (Investor's Business Daily)
09:30AM	Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL) (GlobeNewswire)
Jun-01-26 10:00AM	Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI Data in Multiple Myeloma at ASCO 2026 (GlobeNewswire) -6.08%
May-28-26 12:30PM	J&J's Strategy for Deals on the Cheap Faces a Big Test (The Wall Street Journal)
05:30AM	J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge? (The Wall Street Journal)
May-21-26 05:00PM	Legend Biotech Announces Presentations at ASCO 2026 (GlobeNewswire)
May-12-26 03:00PM	Legend Biotech Corp (LEGN) Q1 2026 Earnings Call Highlights: Strong CARVYKTI Sales and ... (GuruFocus.com) +10.48%
07:00AM	Legend Biotech Reports First Quarter 2026 Results and Recent Highlights (GlobeNewswire)
May-04-26 08:00AM	Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth (GlobeNewswire) +12.34%
Apr-28-26 08:00AM	Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results (GlobeNewswire)
Mar-25-26 01:10PM	Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets (Barrons.com)
Mar-16-26 03:00AM	Genscript Biotech Corp (GNNSF) Full Year 2025 Earnings Call Highlights: Record Revenue Growth ... (GuruFocus.com)
Mar-10-26 03:00PM	Legend Biotech Corp (LEGN) Q4 2025 Earnings Call Highlights: Record Growth and Profitability ... (GuruFocus.com)
07:00AM	Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights (GlobeNewswire)
Feb-24-26 08:00AM	Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results (GlobeNewswire)
Feb-18-26 02:04AM	Barclays Cite Favorable Long-Term Outlook For Legend Biotech Corporation (LEGN) Despite Near-Term Expectation Revisions (Insider Monkey)
Feb-16-26 12:24PM	FDA Guidance on MRD Negativity Bodes Well for Legend Biotech (LEGN) (Insider Monkey)
Feb-07-26 03:33AM	Legend Biotech (LEGN) Shakes Up Board (Insider Monkey)
Feb-02-26 09:38AM	H.C. Wainwright Highlight Curative Potential of Legend Biotech Corporation (LEGN)'s Carvykti Despite Sales Miss (Insider Monkey)
Jan-26-26 03:14AM	Legend Biotech (LEGN) Advances Cell Therapy Innovation and Expands Oncology Pipeline (Insider Monkey)
Jan-22-26 08:00AM	Here Are Thursdays Top Wall Street Analyst Research Calls: Alphabet, Callaway Golf, Datadog, Hyatt Hotels, Palantir, Texas Instruments, Verizon, and More (24/7 Wall St.) -6.84%
Jan-21-26 08:00AM	Legend Biotech to Present CARVYKTI Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use (GlobeNewswire) -11.36%
Jan-12-26 08:00AM	Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-09-26 03:16AM	Cantor Fitzgerald and RBC Capital Stay Bullish on Legend Biotech (LEGN) (Insider Monkey)
Dec-22-25 06:50AM	Here is Why Legend Biotech (LEGN) Offers Such Promising Upside (Insider Monkey)
Dec-17-25 08:00AM	Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-25 07:44AM	Legend Biotech Corporation (LEGN) is an Outperform on Multiple Myeloma Treatment CARVYKTI Prospects (Insider Monkey)
Dec-09-25 03:31PM	Cancer Study Buoys These Small Biotechs (Barrons.com) -8.58%
Dec-06-25 02:00PM	Legend Biotech Highlights New CARVYKTI Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025 (GlobeNewswire)
Nov-27-25 09:00AM	Legend Biotech Awarded 2025 FIBA Foreign Investor of the Year by Flanders Investment & Trade (GlobeNewswire)
Nov-25-25 08:39AM	William Blair Maintains Hold Rating on Legend Biotech (LEGN) Despite Carvykti Label Safety Concerns (Insider Monkey)
Nov-13-25 12:08PM	Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia (GlobeNewswire)
09:21AM	Company News for Nov 13, 2025 (Zacks)
Nov-12-25 02:03PM	Legend Biotech Corp (LEGN) Q3 2025 Earnings Call Highlights: Record CARVYKTI Sales and ... (GuruFocus.com)
07:00AM	Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights (GlobeNewswire)
Nov-10-25 08:16PM	H.C. Wainwright Remains Bullish on Legend Biotech (LEGN), Cites Solid Growth Trajectory for CARVYKTI Therapy (Insider Monkey)
Nov-03-25 11:05AM	Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-29-25 08:00AM	Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results (GlobeNewswire)
Oct-21-25 09:15AM	CorMedix (CRMD) Surges 19.5%: Is This an Indication of Further Gains? (Zacks)
Oct-17-25 09:54PM	J.P. Morgan Maintains a Buy on Legend Biotech Corporation (LEGN) (Insider Monkey)
Oct-08-25 12:57AM	TD Cowen Reiterates a Buy Rating on Legend Biotech Corporation (LEGN) (Insider Monkey)
Sep-30-25 04:00AM	RBC Capital Reiterates a Buy Rating on Legend Biotech Corporation (LEGN) (Insider Monkey)
Aug-26-25 08:00AM	Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-22-25 11:57PM	RBC Capital Lifts PT on Legend Biotech Corporation (LEGN) to $77 From $75 (Insider Monkey)
05:30AM	China's rise in biotech to potentially lower healthcare costs, life science investor says (South China Morning Post)
Aug-18-25 08:00AM	Legend Biotech Appoints Carlos Santos as Chief Financial Officer (GlobeNewswire)
Aug-12-25 07:22AM	Company News for Aug 12, 2025 (Zacks)
03:03AM	Legend Biotech Corp (LEGN) Q2 2025 Earnings Call Highlights: Record CARVYKTI Sales and ... (GuruFocus.com)
Aug-11-25 10:53AM	Key Inflation Data in Focus (Zacks)
10:12AM	Pre-Markets in Green, Inflation Data, Retail Sales, Q2 Earnings This Week (Zacks)
07:00AM	Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights (GlobeNewswire)
Aug-08-25 09:17AM	Legend Biotech Corp (LEGN) Q2 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
Jul-28-25 08:00AM	Legend Biotech to Host Investor Conference Call on Second Quarter 2025 Results (GlobeNewswire)
Jul-18-25 07:24AM	Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains? (Zacks)
Jul-13-25 05:00PM	China Biotechs Stunning Advance Is Changing the Worlds Drug Pipeline (Bloomberg)
Jul-06-25 04:15AM	H.C. Wainwright Maintains a Buy on Legend Biotech (LEGN) With a $75 Price Target (Insider Monkey)
Jun-20-25 04:08PM	The FDA Shake-Up Continues, And Could Impact Genetic Medicines (Investor's Business Daily)
Jun-03-25 10:45AM	Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI in Multiple Myeloma at 2025 ASCO Annual Meeting (GlobeNewswire)
May-22-25 05:15PM	Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT (GlobeNewswire)
May-19-25 08:00AM	Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-14-25 09:18AM	Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension (TipRanks) -10.55%
03:06AM	Legend Biotech Corp (LEGN) Q1 2025 Earnings Call Highlights: Record Growth in CARVYKTI Sales ... (GuruFocus.com)
12:24AM	Q1 2025 Legend Biotech Corp Earnings Call (Thomson Reuters StreetEvents)
May-13-25 07:00AM	Legend Biotech Reports First Quarter 2025 Results and Recent Highlights (GlobeNewswire)
May-12-25 09:20AM	What To Expect From Legend Biotech Corp (LEGN) Q1 2025 Earnings (GuruFocus.com)
May-03-25 04:51AM	The Play On Legend Biotech (Seeking Alpha)
May-02-25 12:00PM	What Makes Legend Biotech (LEGN) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Think Legend Biotech (LEGN) Could Surge 135.16%: Read This Before Placing a Bet (Zacks)
Apr-29-25 08:00AM	Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results (GlobeNewswire)
Apr-24-25 06:53AM	Legend Biotech Corporation (LEGN): Among Takeover Rumors Hedge Funds Are Buying (Insider Monkey)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sanders Corazon (Corsee) D.	Director	Sep 29 '26	Sale	9.46	27,370	258,920	52,731	Oct 01 04:04 PM
Sanders Corazon (Corsee) D.	Director	Sep 29 '26	Proposed Sale	18.92	13,685	258,915		Sep 29 02:31 PM
Santos Carlos E	Chief Financial Officer	Sep 21 '26	Sale	9.14	5,430	49,630	14,246	Sep 23 04:15 PM
Santos Carlos E	Officer	Sep 22 '26	Proposed Sale	18.73	2,715	50,854		Sep 22 03:30 PM
Huang Ying	Former Officer & Director	Sep 22 '26	Proposed Sale	18.65	69,812	1,302,109		Sep 22 02:33 PM
Casey Patrick John	Director	Jun 30 '26	Proposed Sale	29.60	3,000	88,800		Jun 30 10:46 AM
Huang Ying	Chief Executive Officer	Jun 25 '26	Sale	14.78	5,566	82,265	241,872	Jun 29 09:53 PM
Huang Ying	Officer	Jun 26 '26	Proposed Sale	28.39	2,783	79,017		Jun 26 03:23 PM
Huang Ying	Chief Executive Officer	Mar 25 '26	Sale	8.77	9,936	87,139	247,438	Mar 27 04:25 PM
Huang Ying	Officer	Mar 26 '26	Proposed Sale	17.54	4,968	87,149		Mar 26 04:27 PM
Yeung Jessie	Officer	Mar 26 '26	Proposed Sale	17.54	1,862	32,663		Mar 26 04:20 PM
Huang Ying	Officer	Dec 26 '25	Proposed Sale	22.52	64,339	1,449,074		Dec 29 07:28 AM
Sanders Corazon (Corsee) D.	Director	Dec 24 '25	Proposed Sale	22.77	969	22,064		Dec 29 06:45 AM
Huang Ying	Officer	Dec 24 '25	Proposed Sale	22.95	61,467	1,410,606		Dec 29 06:40 AM
GenScript Corporation	Affiliate	Nov 17 '25	Proposed Sale	30.29	203,586	6,166,620		Nov 17 05:50 PM

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Bridgewater, NJ.

Chief Executive OfficerMs. Ingrid Zhang

Chief Financial OfficerMr. Carlos Santos Garcia

J.D.Ms. Ananda Elizabeth Martin Esq.

General CounselMr. Robert Staloff

Interim Head of Research & Development and Senior VP of Regulatory AffairsDr. Yuhong Qiu Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LEGN

Legend Biotech Corp ADR

Upgrade your Finviz experience